Bristol Myers Squibb Company $BMY Shares Purchased by Avantax Planning Partners Inc.

Key Points

• Avantax Planning Partners increased its Bristol Myers Squibb stake by 28.7% in the third quarter, adding 19,342 shares to hold 86,834 shares valued at about $5.4 million.
• Bristol Myers Squibb beat quarterly earnings and revenue estimates, reporting adjusted EPS of $1.35 and revenue of $13.07 billion; revenue rose 6.9% year over year.
• Analysts’ consensus rating is Hold, with an average price target of $65.46. Two company insiders also disclosed share sales.

Avantax Planning Partners Inc. boosted its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 28.7% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 86,834 shares of the biopharmaceutical company's stock after buying an additional 19,342 shares during the quarter. Avantax Planning Partners Inc.'s holdings in Bristol Myers Squibb were worth $5,418,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the stock. Davis Asset Management L.P. purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at $27,000. Addison Advisors LLC acquired a new stake in shares of Bristol Myers Squibb during the second quarter valued at $32,000. William Mack & Associates Inc. purchased a new stake in Bristol Myers Squibb during the 3rd quarter worth about $35,000. Groupe la Francaise increased its position in Bristol Myers Squibb by 562.9% during the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 501 shares in the last quarter. Finally, Kilter Group LLC purchased a new stake in Bristol Myers Squibb during the 2nd quarter worth about $35,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Activity

In related news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Julia A. Haller sold 3,800 shares of the company's stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the transaction, the director directly owned 30,279 shares of the company's stock, valued at $1,916,963.49. This trade represents a 11.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.05% of the company's stock.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Wall Street Analyst Weigh In

A number of research firms have issued reports on BMY. UBS Group lowered shares of Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a report on Wednesday, August 5th. Morgan Stanley decreased their price target on shares of Bristol Myers Squibb from $41.00 to $40.00 and set an "underweight" rating on the stock in a research note on Friday, October 30th. TD Cowen assumed coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a "buy" rating for the company. JPMorgan Chase & Co. boosted their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Finally, Cantor Fitzgerald reduced their price objective on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a "neutral" rating on the stock in a research note on Thursday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $65.46.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $62.20 on Friday. The company has a market cap of $127.15 billion, a P/E ratio of 13.79, a P/E/G ratio of 0.32 and a beta of 0.20. The business has a fifty day simple moving average of $62.34 and a 200-day simple moving average of $60.11. Bristol Myers Squibb Company has a 52 week low of $45.26 and a 52 week high of $68.64. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm had revenue of $13.07 billion for the quarter, compared to the consensus estimate of $12.72 billion. During the same period in the prior year, the business posted $1.63 earnings per share. The firm's revenue for the quarter was up 6.9% compared to the same quarter last year. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.45 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. Bristol Myers Squibb's dividend payout ratio is currently 55.88%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company's medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.